JP2018512164A - 骨髄増殖性障害を処置するための方法 - Google Patents

骨髄増殖性障害を処置するための方法 Download PDF

Info

Publication number
JP2018512164A
JP2018512164A JP2017554345A JP2017554345A JP2018512164A JP 2018512164 A JP2018512164 A JP 2018512164A JP 2017554345 A JP2017554345 A JP 2017554345A JP 2017554345 A JP2017554345 A JP 2017554345A JP 2018512164 A JP2018512164 A JP 2018512164A
Authority
JP
Japan
Prior art keywords
mutation
subject
sap
protein
sap protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017554345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512164A5 (cg-RX-API-DMAC7.html
Inventor
エリザベス トレウ,
エリザベス トレウ,
リチャード エム. ジャック,
リチャード エム. ジャック,
Original Assignee
プロメディオール, インコーポレイテッド
プロメディオール, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロメディオール, インコーポレイテッド, プロメディオール, インコーポレイテッド filed Critical プロメディオール, インコーポレイテッド
Publication of JP2018512164A publication Critical patent/JP2018512164A/ja
Publication of JP2018512164A5 publication Critical patent/JP2018512164A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017554345A 2015-04-15 2016-04-15 骨髄増殖性障害を処置するための方法 Pending JP2018512164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562148005P 2015-04-15 2015-04-15
US62/148,005 2015-04-15
US201562218869P 2015-09-15 2015-09-15
US62/218,869 2015-09-15
PCT/US2016/027773 WO2016168612A1 (en) 2015-04-15 2016-04-15 Methods for treating myeloproliferative disorders

Publications (2)

Publication Number Publication Date
JP2018512164A true JP2018512164A (ja) 2018-05-17
JP2018512164A5 JP2018512164A5 (cg-RX-API-DMAC7.html) 2019-05-23

Family

ID=57127338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554345A Pending JP2018512164A (ja) 2015-04-15 2016-04-15 骨髄増殖性障害を処置するための方法

Country Status (9)

Country Link
US (1) US20180318303A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283655A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018512164A (cg-RX-API-DMAC7.html)
CN (1) CN108138234A (cg-RX-API-DMAC7.html)
AU (1) AU2016248317A1 (cg-RX-API-DMAC7.html)
CA (1) CA2983004A1 (cg-RX-API-DMAC7.html)
HK (2) HK1256036A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017139122A (cg-RX-API-DMAC7.html)
WO (1) WO2016168612A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531793A (ja) * 2018-07-31 2021-11-25 ジェロン・コーポレーションGeron Corporation テロメラーゼ阻害剤による治療から利益を得る可能性が高い患者を特定する方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
JP6852397B2 (ja) * 2016-12-28 2021-03-31 株式会社島津製作所 分析用試料の調製方法および分析方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018160397A1 (en) 2017-03-01 2018-09-07 The Board Of Trustees Of The Leland Stanford Junior University Highly specific circular proximity ligation assay
DE102017107661A1 (de) 2017-04-10 2018-10-11 Universität Rostock SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort
AU2019227979B2 (en) 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
KR101962869B1 (ko) * 2018-08-02 2019-03-27 주식회사 우리메디칼 이미지 분석에 기반한 골수판독 지원 장치
CA3117678A1 (en) * 2018-10-31 2020-05-07 Stemline Therapeutics, Inc. Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
IL328846A (en) * 2019-03-01 2026-08-01 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases
IL285941B1 (en) 2019-03-01 2026-08-01 Allogene Therapeutics Inc Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN
BR112022003553A2 (pt) 2019-08-30 2022-05-24 Allogene Therapeutics Inc Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN111471095B (zh) * 2020-01-15 2021-12-21 上海众启生物科技有限公司 用于阿尔茨海默症自身抗体检测的含jmjd2d蛋白片段的组合物
PE20221757A1 (es) 2020-02-24 2022-11-11 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas
EP3900789A1 (en) * 2020-04-23 2021-10-27 Universitätsklinikum Jena Pharmaceutical combination for the treatment of myeloproliferative neoplasms
CN113549597B (zh) * 2021-07-22 2022-03-25 浙江大学 一种人原发性骨髓纤维化细胞株及其应用
CN114752575B (zh) * 2022-04-07 2023-06-13 内蒙古工业大学 一种nad+依赖性脱氢酶基因及其在提高辅酶q10产量中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting", BUSINESSWIRE, JPN6020017621, 2014, ISSN: 0004405063 *
TEFFERI, A. ET AL., LEUKEMIA, vol. 28, no. 7, JPN6020017626, 2014, pages 1472 - 7, ISSN: 0004405066 *
VAINCHENKER, W. ET AL., BLOOD, vol. 118, no. 7, JPN6020017624, 2011, pages 1723 - 35, ISSN: 0004405065 *
VANNUCCHI, A.M. ET AL., BLOOD, vol. 124, no. 21, JPN6020017623, 2014, pages 405, ISSN: 0004405064 *
VANNUCCHI, A.M. ET AL., THER ADV HEMATOL, vol. 2, no. 1, JPN6020017628, 2011, pages 21 - 32, ISSN: 0004405067 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531793A (ja) * 2018-07-31 2021-11-25 ジェロン・コーポレーションGeron Corporation テロメラーゼ阻害剤による治療から利益を得る可能性が高い患者を特定する方法
JP7401518B2 (ja) 2018-07-31 2023-12-19 ジェロン・コーポレーション テロメラーゼ阻害剤による治療から利益を得る可能性が高い患者を特定する方法

Also Published As

Publication number Publication date
AU2016248317A1 (en) 2017-11-09
CN108138234A (zh) 2018-06-08
WO2016168612A1 (en) 2016-10-20
HK1250752A1 (zh) 2019-01-11
CA2983004A1 (en) 2016-10-20
RU2017139122A (ru) 2019-05-15
RU2017139122A3 (cg-RX-API-DMAC7.html) 2019-08-28
EP3283655A4 (en) 2018-12-05
US20180318303A1 (en) 2018-11-08
EP3283655A1 (en) 2018-02-21
HK1256036A1 (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
CN108138234A (zh) 治疗骨髓增生性障碍的方法
JP7140739B2 (ja) 線維性癌の治療方法
CN108348578B (zh) 用于治疗骨髓增生性病症的方法
EP2874647B1 (en) Method of diagnosis and treatment of metastatic cancer
JP2020516253A (ja) がんのための診断及び治療方法
US20170246298A1 (en) Methods and compositions for cancer treatment and treatment selection
AU2023254992A1 (en) CREBBP related cancer therapy
CN106459181A (zh) α‑烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法
EP3969000B1 (en) Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation
EP4291236A1 (en) Compositions for and methods of preventing metastases
US20250297310A1 (en) Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure
JP2020525019A (ja) 白血病におけるctla4アンタゴニストに対する耐性を同定および治療するための組成物および方法
US20200355684A1 (en) Asprv1 as a neutrophil-specific marker and therapeutic target for inflammatory diseases
HK40069679A (en) Methods for treating fibrotic cancers
HK40039408A (en) Methods for treating fibrotic cancers
HK1226660B (en) Methods for treating fibrotic cancers
HK1226660A1 (en) Methods for treating fibrotic cancers
KR20250065332A (ko) 변형된 stk11 활성 또는 발현을 갖는 암을 치료하기 위한 hdac 억제제
HK1259336B (en) Methods for treating myeloproliferative disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201209